We translate complex oncology trial science into clear, honest language for patients and their families. Antibody-drug conjugates, bispecific antibodies, CAR-T therapy, checkpoint inhibitors — explained without the jargon.
Each explainer covers what the treatment is, how it targets cancer cells, what to expect during a trial using it, and what questions to ask your oncologist.
An ADC combines a monoclonal antibody — which recognises a specific protein on the surface of cancer cells — with a potent chemotherapy payload. The antibody acts as a homing device, guiding the drug specifically to cancer cells and releasing it there, rather than exposing all cells throughout the body.
This explainer includes
Bispecific antibodies are engineered proteins that bind to two different targets at the same time — typically a protein on a cancer cell and a protein on an immune T-cell. By physically linking these two cell types together, the bispecific forces the immune system to recognise and attack the tumour.
This explainer includes
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a personalised treatment. Your own T-cells are removed, genetically modified in a laboratory to carry a receptor that targets a specific cancer protein, then infused back into your body as a living, cancer-hunting therapy. Each batch is made from your own cells.
This explainer includes
Cancer cells can exploit natural immune system "off switches" (checkpoints like PD-1, PD-L1, and CTLA-4) to avoid being destroyed. Checkpoint inhibitors are antibodies that block these switches, restoring the immune system's ability to recognise and attack the tumour. Some patients have long-lasting responses.
This explainer includes
3–6 minute animated explainers covering how each class of oncology treatment works — designed for patients, caregivers, and support groups. Clear narration, no jargon.
Below is an excerpt from a plain-language summary for a Phase II ADC trial — written at a Flesch-Kincaid Grade 7 reading level, suitable for most adult patients.
What is this study trying to find out?
This study is testing whether a new drug — called an antibody-drug conjugate — can help people whose lung cancer has a low level of a protein called HER2. The drug is designed to find cells that have HER2 on their surface, attach to them, and release a powerful cancer-killing medicine directly inside the cancer cell. Researchers want to know how many patients' tumours shrink, how long any benefit lasts, and what side effects occur.
Who can join this study?
You may be able to join if: your lung cancer is non-small cell type; your tumour has tested positive for HER2 (at a low-positive level — your doctor will explain what this means for your biopsy result); you have already had at least one prior treatment; and your general health level (called your ECOG Performance Status) is 0 or 1, meaning you can carry out daily activities with little or no help. Your oncologist will check all criteria with you.
What will happen during the study?
You will receive the study drug through a drip into a vein (intravenous infusion) once every three weeks. Before your first dose, your team will review your medical records and take blood tests. During the study, you will have regular clinic visits — roughly every three weeks — for blood tests, scans (usually every 9 weeks), and check-ins about how you are feeling and any side effects. The study is currently enrolling at [number] research centres across the United States.
KCLG produces custom plain-language trial summaries and video explainers for sponsors, CROs, and site networks. Materials are written to FDA plain-language guidance standards, formatted for IRB submission as patient-facing education documents.
A written summary of your specific study — in plain language, at Grade 6–8 reading level — suitable for patient-facing distribution, IRB submission, and site use during the informed consent process.
A 3–5 minute animated explainer video for your specific study or mechanism of action — narrated in plain language, with on-screen text, designed for patient waiting rooms, navigator toolkits, and digital outreach.
Contact our medical writing team with your protocol synopsis and patient population. We will respond within one business day with a scope and timeline for your patient education materials. Materials are available for any phase of oncology study, any tumour type, and any mechanism of action.